Docoh
Loading...

NRIX Nurix Therapeutics

News

From Benzinga Pro
Nurix Therapeutics Reports Clearance Of Investigational New Drug Application For DeTIL-0255 For Variety Of Solid Tumors
12 Nov 21
Biotech, News, FDA, General
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.
64 Biggest Movers From Yesterday
28 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
Why Did SVB Leerink Beef Up Target Price For Nurix Therapeutics?
27 Oct 21
Biotech, Long Ideas, News, Health Care, Price Target, Small Cap, Analyst Ratings, Movers, Trading Ideas, General
Nurix Shares Gain On Encouraging Early Data From Blood Cancer Trial
27 Oct 21
Biotech, Long Ideas, News, Health Care, Small Cap, Movers, Trading Ideas, General
12 Health Care Stocks Moving In Wednesday's Intraday Session
27 Oct 21
Intraday Update, Markets, Movers
SVB Leerink Maintains Outperform on Nurix Therapeutics, Raises Price Target to $64
27 Oct 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Andrew Berens maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $50 to $64.
44 Stocks Moving In Wednesday's Mid-Day Session
27 Oct 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers AgriFORCE Growing Systems, Ltd. (NASDAQ: AGRI) shares climbed 105.3% to $4.4350. AgriFORCE Growing Systems reported binding LOI to acquire a European agriculture/horticulture and agtech consulting firm for $29 million.
Nurix Therapeutics Will Present Initial Target Degradation Data From First Phase 1 Trial Of NX-2127 In B Cell Malignancies At Targeted Protein Degradation Summit Wednesday, Oct. 27, 2021 At 11:45 a.m. EDT, Will Host Call At 8:30 a.m.
26 Oct 21
Biotech, News, FDA, Events, General
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the Company will present initial pharmacokinetic and pharmacodynamic data
Nurix Therapeutics Q3 EPS $(0.65) Down From $(0.59) YoY, Sales $10.25M Up From $4.08M YoY
14 Oct 21
Earnings, News
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.65) per share. This is a 10.17 percent decrease over losses of $(0.59) per share from the same period last year. The company reported $10.25 million in
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
14 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
SVB Leerink Initiates Coverage On Nurix Therapeutics with Outperform Rating, Announces Price Target of $50
14 Oct 21
News, Price Target, Initiation, Analyst Ratings
SVB Leerink analyst Andrew Berens initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Outperform rating and announces Price Target of $50.

Press releases

From Benzinga Pro
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
12 Nov 21
Press Releases, General
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial Phase 1 clinical trial initiation anticipated by year-end 2021 SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics,
Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference
12 Nov 21
Health Care, Press Releases
DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL Michael T. Lotze, Nurix's chief cellular therapy officer, is
Nurix Therapeutics to Participate in Upcoming Investor Conferences
9 Nov 21
News, Press Releases
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D.,
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies
27 Oct 21
News, Health Care, Press Releases, General
Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127 These data represent the first proof of mechanism of targeted
Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit
26 Oct 21
News, Health Care, Press Releases, General
Presentation to include initial pharmacokinetic and BTK degradation data Company to host conference call at 8:30 a.m. ET on Wednesday, October 27, 2021 SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nurix
Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit
21 Oct 21
News, Health Care, Press Releases
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurix's president and chief
Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
14 Oct 21
Earnings, Press Releases
Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer Expanded Board of Directors with experienced business leaders Strong financial position with $465.4 million as of August
Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders
30 Sep 21
News, Management, Press Releases
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointments of Judith A.